A prospective single-institution study (NCT05787561) is currently investigating the efficacy of targeted therapy in this context using a combination of the MEK/RAF inhibitor avutometinib and the FAK inhibitor defactinib in patients with recurrent mesonephric adenocarcinoma (MA) or mesonephric-like adenocarcinoma (MLA) of gynaecologic origin [66,67]. This evidence concerns the gene MAP2K7 and mesonephric adenocarcinoma.